Effect of GLP-1 Receptor Agonists in the Cardiometabolic Complications in a Rat Model of Postmenopausal PCOS.
Abstract Polycystic Ovary Syndrome (PCOS) is characterized by hyperandrogenism and ovulatory dysfunction. PCOS women have elevated prevalence of cardiometabolic risk factors that worsen after menopause. Liraglutide (Lira), a glucagon-like peptide-1 receptor agonist, have shown beneficial metabolic effects in small clinic trials in reproductive-age PCOS women. We have shown that chronic hyperandrogenemia in an experimental model of postmenopausal PCOS (PCOS) is associated with an adverse cardiometabolic profile and upregulation of the intrarenal renin angiotensin system (RAS). We analyzed the effect of Lira in the ...
Source: Endocrinology - October 8, 2019 Category: Endocrinology Authors: Torres Fernandez ED, Huffman AM, Syed M, Romero DG, Yanes Cardozo LL Tags: Endocrinology Source Type: research

354PAnti-HER-2 therapies and left ventricular dysfunction the renaissance study
ConclusionsWhile the LVD related with AH2 therapies is a real problem in HER2+ breast cancer patients ’ care, a timely diagnosis and t. with therapies for HF can allow LVEF recovery and specific oncological therapy continuance.Legal entity responsible for the studyThe authors.FundingHas not received any funding.DisclosureAll authors have declared no conflicts of interest. (Source: Annals of Oncology)
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research

YangXue QingNao Wan, a Compound Chinese Medicine, Attenuates Cerebrovascular Hyperpermeability and Neuron Injury in Spontaneously Hypertensive Rat: Effect and Mechanism
ConclusionThe overall result shows the potential of YXQNW to attenuate blood–brain barrier (BBB) breakdown in SHR, which involves regulation of energy metabolism and Src/MLCK/MLC signaling. This result provides evidence supporting the application of YXQNW as an adjuvant management for hypertensive patients to prevent hypertensive encephalopathy. (Source: Frontiers in Physiology)
Source: Frontiers in Physiology - October 1, 2019 Category: Physiology Source Type: research

Outcome of HIV Related Kidney Diseases Treated with Combined Antiretroviral Therapy (cART).
Conclusion: Treatment with combined ART and ACEIs slows the progression of HIV-associated kidney disease, decreases proteinuria and improves the GFR. PMID: 31561682 [PubMed - in process] (Source: Journal of the Association of Physicians of India)
Source: Journal of the Association of Physicians of India - September 30, 2019 Category: General Medicine Tags: J Assoc Physicians India Source Type: research

Blockade of Renin Angiotensin System Ameliorates the Cardiac Arrythmias and Sympathetic Neural Remodeling in Hearts of Type 2 DM Rat Model.
CONCLUSIONS: RAS have a role in the cardiac sympathetic nerve sprouting and cardiac arrhythmias induced by type 2 DM and its blockade might have a cardioprotective effect via attenuation of sympathetic nerve fibres remodelling, myocardial norepinephrine contents and oxidative stress. PMID: 31544705 [PubMed - as supplied by publisher] (Source: Endocrine, Metabolic and Immune Disorders Drug Targets)
Source: Endocrine, Metabolic and Immune Disorders Drug Targets - September 24, 2019 Category: Drugs & Pharmacology Tags: Endocr Metab Immune Disord Drug Targets Source Type: research

[Postoperative angioedema induced by angiotensin-converting enzyme inhibitor: case report].
CONCLUSION: Angioedema is a potentially fatal condition when it affects the airway, and should be recognized by anesthesiologists and physicians working in the emergency departments. PMID: 31526514 [PubMed - as supplied by publisher] (Source: Revista Brasileira de Anestesiologia)
Source: Revista Brasileira de Anestesiologia - September 20, 2019 Category: Anesthesiology Tags: Rev Bras Anestesiol Source Type: research

ARNIs: balancing “the good and the bad” of neuroendocrine response to HF
ConclusionsThe beneficial effects of ARNI are related, in part at least, to a positive modulation of the neuroendocrine response to the disease, resulting in an increase of physiological diuresis and dilatation. (Source: Clinical Research in Cardiology)
Source: Clinical Research in Cardiology - September 17, 2019 Category: Cardiology Source Type: research

Association Between Sacubitril/Valsartan Initiation and Health Status Outcomes in Heart Failure With Reduced Ejection Fraction
This study sought to describe the short-term health status benefits of angiotensin-neprilysin inhibitor (ARNI) therapy in patients with heart failure and reduced ejection fraction (HFrEF).BackgroundAlthough therapy with sacubitril/valsartan, a neprilysin inhibitor, improved patients’ health status (compared with enalapril) at 8 months in the PARADIGM-HF (Prospective Comparison of ARNI with ACE inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure) study, the early impact of ARNI on patients’ symptoms, functions, and quality of life is unknown.MethodsHealth status was assesse...
Source: JACC: Heart Failure - September 12, 2019 Category: Cardiology Source Type: research

Efficacy of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in the Preventative Treatment of Episodic Migraine in Adults
AbstractPurpose of ReviewSystematic review of angiotensin-converting enzyme inhibitors (ACE inhibitors) and angiotensin receptor blockers (ARB) in the prophylactic treatment of adults with migraine. To identify gaps in research and provide guidance for future clinical trials.Recent FindingsA search was completed using PubMed, MEDLINE, Embase, and the Cochrane Library January 1, 1990 through December 31, 2017. The following are keywords used in the search: migraine, migraine prophylaxis/prevention, renin-angiotensin-aldosterone system, RAAS, ACE inhibitors, angiotensin-converting enzyme inhibitors: quinapril, perindopril, r...
Source: Current Pain and Headache Reports - September 12, 2019 Category: Neurology Source Type: research

Prognostic Implications of Congestion on Physical Examination Among Contemporary Patients with Heart Failure and Reduced Ejection Fraction:PARADIGM-HF.
We examined the association of the number of signs of congestion (jugular venous distention, edema, rales, and S3) with the primary outcome (cardiovascular death or HF hospitalization), its individual components, and all-cause mortality using time-updated, multivariable-adjusted Cox regression. We further evaluated whether sacubitril/valsartan reduced congestion during follow-up, and whether improvement in congestion is related to changes in clinical outcomes and QoL, assessed by Kansas City Cardiomyopathy Questionnaire clinical summary scores (KCCQ-OSS). Results: Among 8380 participants, 0, 1, 2, and 3+ signs of congestio...
Source: Circulation - September 12, 2019 Category: Cardiology Authors: Selvaraj S, Claggett B, Pozzi A, McMurray JJV, Jhund PS, Packer M, Desai AS, Lewis EF, Vaduganathan M, Lefkowitz MP, Rouleau JL, Shi VC, Zile MR, Swedberg K, Solomon SD Tags: Circulation Source Type: research

PIONEER-HF: a new frontier in the role of neprilysin inhibition in the management of heart failure with reduced ejection fraction
The addition of a neprilysin inhibitor to a renin –angiotensin system (RAS) antagonist, using the combination of sacubitril and valsartan, was shown to reduce morbidity and mortality in outpatients with chronic heart failure and reduced ejection fraction (HFrEF).1 In PARADIGM-HF (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure trial), sacubitril/valsartan reduced the risk of cardiovascular death or heart failure (HF) hospitalization by 20%, compared with a RAS blocker alone [the gold-standard angiotensin-converting enzyme (ACE)-inhibitor enalapril]. Cons...
Source: Cardiovascular Research - September 8, 2019 Category: Cardiology Source Type: research

Dipeptidyl peptidase-4 inhibitors can inhibit angiotensin converting enzyme.
Abstract Angiotensin-1 converting enzyme inhibitors (ACEIs) improve insulin sensitivity. Inhibitors of dipeptidyl peptidase-4 (DPP-4) are anti-diabetic drugs with several cardio-renal effects. Both ACE and DPP-4 share common features and so we tested if they could be inhibited by one inhibitor. First, in silico screening was used to investigate the ability of different DPP-4 inhibitors or ACEIs to interact with DPP-4 and ACE. The results of screening were then extrapolated into animal study. Fifty Sprague Dawley rat were randomly assigned into 5 groups treated with vehicle, captopril, enalapril, linagliptin or sit...
Source: European Journal of Pharmacology - September 3, 2019 Category: Drugs & Pharmacology Authors: Abouelkheir M, El-Metwally TH Tags: Eur J Pharmacol Source Type: research

Effect of Sacubitril-Valsartan vs Enalapril on Aortic Stiffness in Heart Failure and Reduced Ejection Fraction
This randomized trial compares the effects of sacubitril-valsartan vs enalapril on central aortic stiffness and other physiologic indexes in patients with heart failure and reduced ejection fraction. (Source: JAMA - Journal of the American Medical Association)
Source: JAMA - Journal of the American Medical Association - September 2, 2019 Category: General Medicine Source Type: research

[Effects of changing the appearance of medications in safety and adherence in chronic patients over 65 years of age in primary care. CAMBIMED Study].
CONCLUSIONS: The changes made in bioequivalent drugs with different appearance could increase the number of medication use errors and decrease the adherence. More studies should be carried out to assess how much this affects the control of the disease. The intervention section is not considered because it is an observational study. PMID: 31481266 [PubMed - as supplied by publisher] (Source: Atencion Primaria)
Source: Atencion Primaria - August 31, 2019 Category: Primary Care Authors: Arancón-Monge JM, de Castro-Cuenca A, Serrano-Vázquez Á, Campos-Díaz L, Rodríguez Barrientos R, Del Cura-González I, Grupo CAMBIMED, Integrantes del Grupo CAMBIMED Tags: Aten Primaria Source Type: research

Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial
Publication date: 24–30 August 2019Source: The Lancet, Volume 394, Issue 10199Author(s): Gholamreza Roshandel, Masoud Khoshnia, Hossein Poustchi, Karla Hemming, Farin Kamangar, Abdolsamad Gharavi, Mohammad Reza Ostovaneh, Alireza Nateghi, Masoud Majed, Behrooz Navabakhsh, Shahin Merat, Akram Pourshams, Mahdi Nalini, Fatemeh Malekzadeh, Masoumeh Sadeghi, Noushin Mohammadifard, Nizal Sarrafzadegan, Mohammad Naemi-Tabiei, Abdolreza Fazel, Paul BrennanSummaryBackgroundA fixed-dose combination therapy (polypill strategy) has been proposed as an approach to reduce the burden of cardiovascular disease, especially in low-inc...
Source: The Lancet - August 23, 2019 Category: General Medicine Source Type: research

Intestinal angioedema from angiotensin converting enzyme inhibitor
A 41-year-old Congolese woman born in 1977 presented in February 2018 to our emergency department with severe abdominal pain. Her medical history was notable for idiopathic collapsing glomerulopathy for which she was being initially treated with corticosteroids, later switched to tacrolimus. Additionally she was on candesartan 16 mg/d, then later switched in 2014 to enalapril 20 mg/d. During 2017, she was poorly compliant with her medications. In February 2018, her medications included tacrolimus, furosemide, spironolactone, lercanidipine, and enalapril. (Source: Kidney International)
Source: Kidney International - August 21, 2019 Category: Urology & Nephrology Authors: Valentine Gillion, Cristina Anca Dragean, G éraldine Dahlqvist, Michel Jadoul Tags: Nephrology Image Source Type: research

Sacubitril/Valsartan: Updates and Clinical Evidence for a Disease-Modifying Approach
AbstractNew therapeutic strategies aimed to tackle the rising socio-economic burden of heart failure (HF) have become an impelling priority. The new pharmacological class of angiotensin (Ang) receptor-neprilysin inhibitors (ARNI) prompted a real conceptual change in the treatment of HF moving from only the inhibition of the renin-Ang-aldosterone system and sympathetic nervous system to a strategy based on the concomitant pharmacological enhancement of endogenous natriuretic peptides. Sacubitril/valsartan, a first-in-class ARNI, has reduced the primary composite endpoint of cardiovascular death or HF hospitalisation, sudden...
Source: Drugs - August 20, 2019 Category: Drugs & Pharmacology Source Type: research

Relative Bioavailability of Enalapril Administered as Orodispersible Minitablets in Healthy Adults
AbstractThe angiotensin ‐converting enzyme inhibitor enalapril is commonly used to treat chronic heart failure in children. Because some children are unable to swallow capsules or tablets, a new, age‐appropriate, orodispersible minitablet (ODMT) containing 1 mg of enalapril was developed within the EU‐funded LENA (L abeling of Enalapril from Neonates up to Adolescents) consortium. In order to support the clinical evaluation of this new formulation in children, a relative bioavailability study was performed in healthy adults, comparing the bioavailability of enalapril in the ODMT with that of a reference product ...
Source: Clinical Pharmacology in Drug Development - August 14, 2019 Category: Drugs & Pharmacology Authors: Anne Hecken, Bj örn B. Burckhardt, Feras Khalil, Jan Hoon, Ingrid Klingmann, Marissa Herbots, Stephanie Laeer, Florian B. Lagler, Jörg Breitkreutz Tags: Original Manuscript Source Type: research

Use of rivaroxaban for treatment of cranial vena cava syndrome secondary to transvenous pacemaker lead thrombosis in a dog
Publication date: Available online 25 July 2019Source: Journal of Veterinary CardiologyAuthor(s): B.L. Miranda, R. Walton, D.N. LeVine, A. Blong, W. Ware, J. WardAbstractA six-year-old Brussels griffon was presented for cervical swelling three months after implantation of a transvenous pacemaker. Transthoracic echocardiography demonstrated a thrombus associated with the pacemaker lead, partially obstructing right atrial inflow. The laboratory findings were consistent with protein-losing nephropathy. Initial medical therapy consisted of rivaroxaban (0.68 mg/kg PO q 24 hr), clopidogrel (2.5 mg/kg PO q 24 ...
Source: Journal of Veterinary Cardiology - August 9, 2019 Category: Veterinary Research Source Type: research

Early Effects of Starting Doses of Enalapril in Patients with Chronic Heart Failure in the SOLVD Treatment Trial
In the Studies of Left Ventricular Dysfunction (SOLVD) Treatment trial, similar clinical benefits were observed between starting doses of enalapril and the target dose achieved by post-randomization up-titration. In our current analysis, protecting the randomization, we examined the early effects of starting doses of enalapril. (Source: The American Journal of Medicine)
Source: The American Journal of Medicine - August 8, 2019 Category: General Medicine Authors: Phillip H. Lam, Milton Packer, Gregg C. Fonarow, Charles Faselis, Richard M. Allman, Charity J. Morgan, Steven Singh, Bertram Pitt, Ali Ahmed Tags: Clinical Research Study Source Type: research

A Pilot Study: Decreased Hospitalization in Elderly Heart Failure Patients While on Sacubitril-Valsartan Combination
Sacubitril-Valsartan combination (SVC) is new to the heart failure (HF) armamentarium. SVC, in addition to HF goal directed medical therapy (GDMT), is indicated to reduce the risk of cardiovascular (CV) death and HF hospitalizations in patients with reduced ejection fraction (HFrEF). PARADIGM-HF was stopped early due to overwhelming efficacy when compared to Enalapril. SVC dosed to the target 97/103 mg twice daily, reduced the primary composite outcomes of CV death or first HF hospitalization by 20%. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - August 1, 2019 Category: Cardiology Authors: Tamra L. Ward, Teresa Bueno, Simon Leung, Maria Avila, Priyanka Gosain, Crystal Ayala, Ioana Dumitru Tags: 433 Source Type: research

Representativeness of the PIONEER-HF Clinical Trial Population in Patients Hospitalized with Heart Failure
In this study, we aimed to: (1) determine eligibility for the PIONEER-HF trial among patients in a contemporary registry population with ADHF and HF with reduced ejection fraction ( ”all HFrEF”), (2) determine eligibility for sacubitril/valsartan using criteria most relevant to daily clinical practice (“actionable” cohort), and (3) compare long-term outcomes between the all HFrEF, PIONEER-HF trial eligible, and actionable cohorts using linked Medicare claims data. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - August 1, 2019 Category: Cardiology Authors: Sabina Sayeed, Marat Fudim, Haolin Xu, Roland Matsouaka, Paul A. Heidenreich, Clyde W. Yancy, Gregg C. Fonarow, Eric J. Velazquez, Adrian F. Hernandez, Adam D. DeVore Tags: 419 Source Type: research

Evaluation of Sacubitril/Valsartan Prescribing and Monitoring at a Veterans Affairs Hospital
Heart Failure (HF) readmissions is a burden to the patient, family and healthcare system. The PARADIGM-HF trial demonstrated that patients on maintenance doses of sacubitril/valsartan 97/103 mg twice daily experienced a reduction in cardiovascular mortality and heart failure hospitalizations compared with enalapril. The Veterans Affairs (VA) Pharmacy Benefit Management (PBM) criteria for use recommends that patients follow-up with a provider within two to four weeks of therapy initiation for serum potassium, renal function, and blood pressure monitoring, and to ensure dose titration to the target maintenance dose. (Source:...
Source: Journal of Cardiac Failure - August 1, 2019 Category: Cardiology Authors: Inela Masic, Christina W. Quillian, Sue Kim Tags: 330 Source Type: research

Safety of Initiation of Sacubitril/Valsartan in ICU Patients with Advanced Decompensated Heart Failure
Sacubitril/valsartan (S/V) is superior to enalapril in reducing mortality and morbidity in patients with chronic stable heart failure with reduced ejection fraction (HFrEF). The goal of this investigation was to determine if S/V could be used safely as an oral vasodilator when weaning intravenous vasoactive therapies. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - August 1, 2019 Category: Cardiology Authors: Dmitry M. Yaranov, Chonyang L. Albert, Matthew H. Gonzalez, Trejeeve Martyn, Kathleen Faulkenberg, W.H. Wilson Tang, Randall Starling Tags: 192 Source Type: research

Comparative effects of enalapril versus perindopril on serum levels of leptin and adiponectin in hypertensive patients.
Conclusions: Our results indicate that perindopril is superior to enalapril when it comes to its effect on the human adipose-tissue-derived hormones. This suggests that angiotensin-converting enzyme inhibitors improves the adipokine profile, possibly allowing beneficial effects to hypertensive individuals. PMID: 31345107 [PubMed - as supplied by publisher] (Source: Acta Cardiologica)
Source: Acta Cardiologica - July 28, 2019 Category: Cardiology Tags: Acta Cardiol Source Type: research

Use of rivaroxaban for treatment of cranial vena caval syndrome secondary to transvenous pacemaker lead thrombosis in a dog
Publication date: Available online 25 July 2019Source: Journal of Veterinary CardiologyAuthor(s): Becky Lozada Miranda, Rebecca Walton, Dana N. LeVine, April Blong, Wendy Ware, Jessica WardAbstractA six-year-old Brussels Griffon was presented for cervical swelling three months after implantation of a transvenous pacemaker. Transthoracic echocardiography demonstrated a thrombus associated with the pacemaker lead, partially obstructing right atrial inflow. Laboratory findings were consistent with protein-losing nephropathy. Initial medical therapy consisted of rivaroxaban (0.68 mg/kg PO q 24 hr), clopidogrel (2.5 mg/kg PO q ...
Source: Journal of Veterinary Cardiology - July 25, 2019 Category: Veterinary Research Source Type: research

Clinical Features of Graves' Ophthalmopathy and impact of Enalapril on the Course of Mild Graves' Ophthalmopathy: A pilot study.
CONCLUSION: Our results showed that Enalapril treatment could ameliorate the clinical course of GO according to the ophthalmologic examinations and subjective parameters of disease progression. However, further studies should be performed to determine the efficacy of Enalapril in Graves' ophthalmopathy treatment. PMID: 31345156 [PubMed - as supplied by publisher] (Source: Endocrine, Metabolic and Immune Disorders Drug Targets)
Source: Endocrine, Metabolic and Immune Disorders Drug Targets - July 25, 2019 Category: Endocrinology Authors: Ataabadi G, Dabbaghmanesh MH, Owji N, Bakhshayeshkaram M, Montazeri-Najafabady N Tags: Endocr Metab Immune Disord Drug Targets Source Type: research

Loquat leaf polysaccharides improve glomerular injury in rats with anti-Thy 1 nephritis via peroxisome proliferator-activated receptor alpha pathway.
Authors: Lu T, Fan Z, Hou J, Qi X, Guo M, Ju J, Yang Y, Gu C Abstract Chronic glomerulonephritis frequently develops into renal failure that cannot be completely cured. Based on the success of anti-inflammatory Chinese herbs in treating chronic nephritis, our goal was to investigate the therapeutic effects and mechanism of action of loquat leaf polysaccharides (LLPS) on chronic anti-Thy-1 nephritis. A rat model of glomerulonephritis was used to study the effects of 8 weeks of enalapril or LLPS treatment. Twenty-four-hour rat urinary protein excretions were measured every week for 8 weeks. Then, all animals were sac...
Source: American Journal of Translational Research - July 19, 2019 Category: Research Tags: Am J Transl Res Source Type: research

Fanconi syndrome due to tenofovir disoproxil fumarate (TDF) after liver transplantation
A 55  year-old man with a previous medical history of hepatitis B virus (HBV) and hepatitis D virus (HDV) infection with decompensated cirrhosis underwent liver transplant (LT) in June 2018. Two weeks after an uneventful liver transplant the patient was taking tacrolimus 9 mg/day, mycophenolate mofet il 360 mg/12 h and prednisone 10 mg/day as part of immunosuppressive therapy, cotrimoxazole 160/800 mg/day, calcium/vitamin D, folic acid 5 mg/day, enalapril 5 mg/day, insulin and TDF 245 mg/day, the latter as a prophylaxis for hepatitis B. (Source: Digestive and Liver Disease)
Source: Digestive and Liver Disease - July 13, 2019 Category: Gastroenterology Authors: Joan Llach, Marta G ómez-Hernando, Jordi Colmenero, Xavier Forns Tags: Correspondence Source Type: research

Trends in Kidney Function Outcomes Following RAAS Inhibition in Patients With Heart Failure With Reduced Ejection Fraction
Publication date: Available online 11 July 2019Source: American Journal of Kidney DiseasesAuthor(s): Wendy McCallum, Hocine Tighiouart, Elaine Ku, Deeb Salem, Mark J. SarnakRationale & ObjectiveAngiotensin-converting enzyme (ACE) inhibitors are beneficial in heart failure with reduced ejection fraction (HFrEF). We sought to describe longitudinal trends in estimated glomerular filtration rate (eGFR) in HFrEF and how ACE-inhibitor therapy influences these changes.Study DesignPost hoc analysis of trial data.Settings & ParticipantsSymptomatic (Treatment Trial, n = 2,423) and asymptomatic (Prevention Trial, n&...
Source: American Journal of Kidney Diseases - July 12, 2019 Category: Urology & Nephrology Source Type: research

Sacubitril/valsartan: A practical guide
Publication date: May 2019Source: Revista Portuguesa de Cardiologia (English Edition), Volume 38, Issue 5Author(s): Cândida Fonseca, Dulce Brito, Jorge Ferreira, Fátima Franco, João Morais, José Silva Cardoso, Experts opinion, endorsed by the Working Group on Heart Failure of the Portuguese Society of cardiologyAbstractRenin-angiotensin-aldosterone system (RAAS) inhibitors are a cornerstone in the treatment of heart failure with reduced ejection fraction (HFrEF). Sacubitril/valsartan modulates the neurohormonal axis by inhibiting both angiotensin receptors and neprilysin, and improves neurohormon...
Source: Revista Portuguesa de Cardiologia - July 6, 2019 Category: Cardiology Source Type: research

BAOXIN Granules Protected Mouse Model With Elevated Afterload From Cardiac Hypertrophy by Suppressing Both Inflammatory Reaction and Collagen Deposition
Baoxin Pill was reported to be effective clinically for chronic heart failure based on the principles of Traditional Chinese Medicine (TCM), invigorating qi and activating blood. The present study evaluated preclinically the effects of the improved dosage form, Baoxin Granules, on cardiac hypertrophy. Transverse aortic constriction (TAC) was performed in mice to model cardiac hypertrophy by aortic stenosis for 4 weeks. The sham and TAC group were intragastrically administrated with saline as the controls. Two treatment groups were administrated orally with 10mg/kg•d Enalapril (positive control) or 0.77g/kg•d Baox...
Source: Frontiers in Physiology - July 5, 2019 Category: Physiology Source Type: research

Renin-angiotensin System Blockade Therapy for Early Renal Involvement in MYH9-related Disease with an E1841K Mutation: A Case Report.
Authors: Tanaka M, Miki S, Saita H, Shimada H, Nishikawa S, Taniguchi K, Hagihara K, Iwanari S, Ikeda M, Kunishima S, Takeoka H Abstract MYH9-related disease is a rare genetic disorder characterized by macrothrombocytopenia, with frequent proteinuric nephropathy, hearing loss, and cataract. Although proteinuric nephropathy usually progresses to renal failure, there is no established treatment for the nephropathy. We herein describe the case of a 19-year-old man carrying an E1841K MYH9 mutation, who developed persistent proteinuria. The patient was diagnosed with early-stage MYH9-related nephropathy based on the his...
Source: Internal Medicine - June 29, 2019 Category: Internal Medicine Tags: Intern Med Source Type: research

Cardioprotective effects of Plinia cauliflora (Mart.) Kausel in a rabbit model of doxorubicin-induced heart failure
ConclusionThe present study demonstrated that EEPC may prevent doxorubicin-induced heart failure by modulating the antioxidant defense system, reducing reactive oxygen species-induced damage, preventing alterations of hemodynamic and endothelial function, and preventing damage to the cardiac structure. EEPC, especially at the highest dose tested, may be considered a cardioprotective coadjuvant to prevent doxorubicin-induced cardiotoxicity.Graphical abstract (Source: Journal of Ethnopharmacology)
Source: Journal of Ethnopharmacology - June 28, 2019 Category: Drugs & Pharmacology Source Type: research

Correction: Drugs for Chronic Heart Failure
Date: July 1, 2019 Issue #:  1575Summary:  In our Drugs for Chronic Heart Failure article,1 our description of the PARADIGM-HF trial comparing the combination of the ARB valsartan and the neprilysin inhibitor sacubitril(Entresto) with the ACE inhibitor enalapril for treatment of heart failure with reduced ejection fraction (HFrEF) characterized the dosage of enalapril as " suboptimal " . Some readers have objected to that characterization.The FDA-approved dosage of enalapril for treatment of HFrEF is 2.5-20 mg twice daily. In PARADIGM-HF, the dosage was capped at 10 mg twice daily, a ...
Source: The Medical Letter - June 24, 2019 Category: Drugs & Pharmacology Authors: admin Tags: ACE inhibitors ARBs Enalapril Entresto Heart Failure sacubitril Valsartan Source Type: research

Initiation of Sacubitril/Valsartan in Patients with De Novo Heart Failure with Reduced Ejection Fraction: An Analysis of the Transition Study
Background: Initiation of sacubitril/valsartan (S/V) in hospitalised patients with heart failure (HF) with reduced ejection fraction (HFrEF), stabilised after admission due to decompensated HF (ADHF), was associated with superior NT-proBNP reduction compared to enalapril in the PIONEER-HF study. Treatment effect was similar in patients with and without a prior diagnosis of HFrEF. (Source: Heart, Lung and Circulation)
Source: Heart, Lung and Circulation - June 24, 2019 Category: Cardiology Authors: R. Wachter, S. Michele, K. Witte, E. Straburzynska-Migaj, J. Belohlavek, C. Fonseca, C. Mueller, E. Lonn, W. Bao, A. Noe, H. Schwende, D. Butylin, D. Pascual-Figal, on behalf of TRANSITION investigators Tags: 102 Source Type: research

In-Hospital Initiation of Sacubitril/Valsartan in Stabilised Patients with Heart Failure and Reduced Ejection Fraction Na ïve to Renin-Angiotensin System Blocker: An Analysis of the Transition Study
Background: In the PIONEER-HF study, in-hospital initiation of sacubitril/valsartan (S/V) versus enalapril in patients with heart failure (HF) and reduced ejection fraction (HFrEF), stabilised after acute decompensation, was associated with superior reduction of NT-proBNP, irrespective of prior use of angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB). (Source: Heart, Lung and Circulation)
Source: Heart, Lung and Circulation - June 24, 2019 Category: Cardiology Authors: R. Wachter, S. Michele, K. Witte, E. Straburzynska-Migaj, J. Belohlavek, C. Fonseca, C. Mueller, E. Lonn, W. Bao, A. Noe, H. Schwende, D. Butylin, D. Pascual-Figal, on behalf of TRANSITION investigators Tags: 101 Source Type: research

Cost-effectiveness of sacubitril/valsartan for the treatment of patients with heart failure with reduced ejection fraction in Portugal.
Conclusion: Sacubitril/valsartan is a cost-effective therapeutic option in the treatment of Portuguese patients with HFrEF and translate into significant health gains and increased life expectancy versus the current standard of care. PMID: 31219361 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - June 22, 2019 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Sacubitril/valsartan eligibility and outcomes in the ESC ‐EORP‐HFA Heart Failure Long‐Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM‐HF trial, ESC guidelines, and real world
ConclusionsAmong outpatients with HFrEF in the ESC ‐EORP‐HFA HF‐LT Registry, 84% met label criteria, while only 12% and 28% met PARADIGM‐HF and guideline criteria for LCZ696 if requiring ≥ 20 mg and ≥ 10 mg enalapril, respectively. Registry patients eligible for LCZ696 had greater heart failure hospitalization but lower mortality rates than the PARADIGM‐HF enalapril group. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - June 18, 2019 Category: Cardiology Authors: Chris J. Kapelios, Mitja Lainscak, Gianluigi Savarese, C écile Laroche, Petar Seferovic, Frank Ruschitzka, Andrew Coats, Stefan D. Anker, Maria G. Crespo‐Leiro, Gerasimos Filippatos, Massimo F. Piepoli, Giuseppe Rosano, Luisa Zanolla, Carl Tags: Research Article Source Type: research

Acute declines in estimated glomerular filtration rate on enalapril and mortality and cardiovascular outcomes in patients with heart failure with reduced ejection fraction
Angiotensin-converting enzyme inhibitors are beneficial in heart failure with reduced ejection fraction but are associated with acute declines in estimated glomerular filtration rate (eGFR). Prior studies evaluating thresholds of eGFR decline while using angiotensin-converting enzyme inhibitors in heart failure with reduced ejection have not taken into account this medication-driven decline. Here we used data from the Studies of Left Ventricular Dysfunction (SOLVD) trial of 6245 patients and performed Cox proportional hazards regression models to calculate hazard ratios of all-cause mortality and heart failure hospitalizat...
Source: Kidney International - June 10, 2019 Category: Urology & Nephrology Authors: Wendy McCallum, Hocine Tighiouart, Elaine Ku, Deeb Salem, Mark J. Sarnak Tags: Clinical Investigation Source Type: research

Sacubitril/Valsartan in Asian Patients with Heart Failure with Reduced Ejection Fraction.
Authors: Dewan P, Docherty KF, McMurray JJV Abstract The Prospective comparison of Angiotensin Receptor-neprilysin inhibitor (ARNI) with Angiotensin converting enzyme inhibitor (ACEI) to Determine Impact on Global Mortality and morbidity in Heart Failure (HF) trial (PARADIGM-HF) showed that adding a neprilysin inhibitor (sacubitril) to a renin-angiotensin system blocker (and other standard therapy) reduced morbidity and mortality in ambulatory patients with chronic HF with reduced ejection fraction (HFrEF). In PARADIGM-HF, valsartan combined with sacubitril (a so-called ARNI) was superior to the current gold standa...
Source: Korean Circulation Journal - June 8, 2019 Category: Cardiology Tags: Korean Circ J Source Type: research

Lycium barbarum polysaccharides attenuate rat anti-Thy-1 glomerulonephritis through mediating pyruvate dehydrogenase
Publication date: August 2019Source: Biomedicine & Pharmacotherapy, Volume 116Author(s): Ting Lu, Wen-e Zhao, Fang Zhang, Xiaohong Qi, Ye Yang, Chunyan GuAbstractGlomerulonephritis is the major cause of chronic kidney disease characterized by mesangial cell proliferation and extracellular matrix deposition. The aim of this study was to investigate the effects of Lycium barbarum polysaccharides (LBPs) on anti-Thy 1 nephritis rats and explore the protective mechanism of LBPs. After the model of glomerulonephritis created by injecting anti-thymocyte serum (ATS), rats were treated with enalapril or LBPs for 8 weeks. The th...
Source: Biomedicine and Pharmacotherapy - May 30, 2019 Category: Drugs & Pharmacology Source Type: research

Lycium barbarum polysaccharides attenuate rat anti-Thy-1 glomerulonephritis through mediating pyruvate dehydrogenase.
Abstract Glomerulonephritis is the major cause of chronic kidney disease characterized by mesangial cell proliferation and extracellular matrix deposition. The aim of this study was to investigate the effects of Lycium barbarum polysaccharides (LBPs) on anti-Thy 1 nephritis rats and explore the protective mechanism of LBPs. After the model of glomerulonephritis created by injecting anti-thymocyte serum (ATS), rats were treated with enalapril or LBPs for 8 weeks. The therapeutic effect was evaluated by detection of renal-related biochemical parameters, histological observation and markers of renal fibrosis. Moreove...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - May 29, 2019 Category: Drugs & Pharmacology Authors: Lu T, Zhao WE, Zhang F, Qi X, Yang Y, Gu C Tags: Biomed Pharmacother Source Type: research

Sacubitril/valsartan eligibility and outcomes in the ESC HFA EORP Heart Failure Long ‐Term Registry: bridging between EMA/FDA label, the PARADIGM‐HF trial, ESC Guidelines, and real‐world
ConclusionsAmong outpatients with HFrEF in the ESC ‐HFA‐HF‐LT registry, 84% met label criteria, while only 12% and 28% met PARADIGM‐HF and Guidelines criteria for LCZ696 if requiring ≥20 mg and ≥10 mg enalapril, respectively. Registry patients eligible for LCZ696 had greater HF hospitalization but lower mortality rates then the PARADIGM‐ HF enalapril group. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - May 27, 2019 Category: Cardiology Authors: Chris J. Kapelios, Mitja Lainscak, Gianluigi Savarese, C écile Laroche, Petar Seferovic, Frank Ruschitzka, Andrew Coats, Stefan D. Anker, Maria G. Crespo‐Leiro, Gerasimos Filippatos, Massimo F. Piepoli, Giuseppe Rosano, Luisa Zanolla, Carl Tags: Research Article Source Type: research

Neurohormonal modulation: The new paradigm of pharmacological treatment of heart failure
Publication date: March 2019Source: Revista Portuguesa de Cardiologia (English Edition), Volume 38, Issue 3Author(s): J. Silva-Cardoso, D. Brás, F. Canário-Almeida, A. Andrade, L. Oliveira, F. Pádua, C. Fonseca, N. Bragança, S. Carvalho, R. Soares, J. Ferreira SantosAbstractThe current paradigm of medical therapy for heart failure with reduced ejection fraction (HFrEF) is triple neurohormonal blockade with an angiotensin-converting enzyme inhibitor (ACEI), a beta-blocker (BB) and a mineralocorticoid receptor antagonist (MRA). However, three-year mortality remains over 30%.Stimulation of counter-...
Source: Revista Portuguesa de Cardiologia - May 23, 2019 Category: Cardiology Source Type: research

Are healthcare systems now ready to adopt sacubitril/valsartan as the preferred approach to inhibiting the renin –angiotensin system in chronic heart failure? The culmination of a 20-year journey
This editorial refers to ‘Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril–valsartan or enalapril in the PIONEER-HF trial’††, by D.A. Morrowet al., on page3345. (Source: European Heart Journal)
Source: European Heart Journal - May 23, 2019 Category: Cardiology Source Type: research

Extent of extemporaneous compounding and pattern of prescribing and use of extemporaneous medicines in a developing setting
ConclusionsThe extent of compounding and use of extemporaneous products is considerable and remain an importance source of critical access to essential medicines for children with cardiovascular and neurological disorders, and electrolyte imbalance and nutritional deficiencies in both the inpatient and ambulatory settings. However, the limited access to information on the stability, efficacy and safety of extemporaneous products may potentially expose patients to harm. (Source: Journal of Pharmaceutical Health Services Research)
Source: Journal of Pharmaceutical Health Services Research - May 16, 2019 Category: Drugs & Pharmacology Authors: Kazeem B. Yusuff Tags: Research Paper Source Type: research